GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » EV-to-FCF

Pangaea Oncology (XMAD:PANG) EV-to-FCF : -20.62 (As of Apr. 22, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pangaea Oncology's Enterprise Value is €60.94 Mil. Pangaea Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.96 Mil. Therefore, Pangaea Oncology's EV-to-FCF for today is -20.62.

The historical rank and industry rank for Pangaea Oncology's EV-to-FCF or its related term are showing as below:

XMAD:PANG' s EV-to-FCF Range Over the Past 10 Years
Min: -27.24   Med: -14.03   Max: -3.87
Current: -20.62

During the past 11 years, the highest EV-to-FCF of Pangaea Oncology was -3.87. The lowest was -27.24. And the median was -14.03.

XMAD:PANG's EV-to-FCF is ranked worse than
100% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 22.875 vs XMAD:PANG: -20.62

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-22), Pangaea Oncology's stock price is €1.68. Pangaea Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.177. Therefore, Pangaea Oncology's PE Ratio (TTM) for today is At Loss.


Pangaea Oncology EV-to-FCF Historical Data

The historical data trend for Pangaea Oncology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangaea Oncology EV-to-FCF Chart

Pangaea Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.73 -18.00 -14.73 -10.87 -17.94

Pangaea Oncology Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -10.87 - -17.94 -

Competitive Comparison of Pangaea Oncology's EV-to-FCF

For the Diagnostics & Research subindustry, Pangaea Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pangaea Oncology's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pangaea Oncology's EV-to-FCF falls into.


;
;

Pangaea Oncology EV-to-FCF Calculation

Pangaea Oncology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=60.940/-2.956
=-20.62

Pangaea Oncology's current Enterprise Value is €60.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-2.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pangaea Oncology  (XMAD:PANG) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pangaea Oncology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.68/-0.177
=At Loss

Pangaea Oncology's share price for today is €1.68.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pangaea Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.177.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pangaea Oncology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pangaea Oncology Business Description

Traded in Other Exchanges
N/A
Address
Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology Headlines

No Headlines